In recent years, the scientific community has increasingly recognized obesity not merely as a metabolic disorder but as a chronic, low-grade systemic inflammatory condition. This evolving perspective has profound implications for understanding the complex interactions between metabolism, immunity, and inflammation. Central to this discussion is the role of easily accessible immune-inflammatory markers derived from routine blood tests, which hold promise for reflecting the subtle inflammatory milieu associated with obesity. Yet, the reliability and accuracy of such indices—specifically the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), systemic immune-inflammation index (SII), and systemic inflammation response index (SIRI)—remain a subject of ongoing debate and investigation.
A newly published systematic review and meta-analysis by Yang et al. delves deeply into this controversy, offering a comprehensive evaluation of immune-inflammatory biomarkers in adults with obesity compared to non-obese counterparts. The authors meticulously aggregated data from multiple studies, harnessing the power of meta-analytic techniques to clarify whether these hematological indices can serve as reliable surrogates for obesity-associated inflammation. This work stands as a critical juncture in obesity research, as it systematically examines not only the associations but also the underlying sources of heterogeneity contributing to inconsistent findings in previous literature.
Obesity is characterized by a persistent state of low-grade inflammation, distinguished from the overt inflammation seen in infections by its subtle, chronic nature. This inflammatory phenotype involves a complex interplay of immune cells, adipocytes, and adipose tissue-resident macrophages, contributing to the release of pro-inflammatory cytokines such as TNF-alpha, IL-6, and CRP. These systemic signals, although modest in magnitude, have measurable effects on metabolic pathways, immunity, and cardiovascular risk profiles, underscoring the need for dependable clinical markers to monitor inflammation in obese individuals.
NLR and PLR have emerged as cost-effective, accessible indices derived from routine complete blood counts (CBC), posited as indicators of systemic inflammation. The neutrophil-to-lymphocyte ratio encapsulates the balance between innate immune activation and adaptive immune regulation, with neutrophils representing acute inflammatory response and lymphocytes reflecting immune competence. Similarly, PLR considers platelets, which not only participate in hemostasis but also modulate inflammatory processes, against lymphocyte counts. Together, these ratios are gaining traction for their simplicity and prognostic value in various inflammatory and cardiovascular disorders.
Beyond these traditional markers, the systemic immune-inflammation index (SII) integrates three parameters—neutrophils, lymphocytes, and platelets—into a composite score designed to provide a more holistic view of systemic inflammation and immune response. The systemic inflammation response index (SIRI) takes a slightly different approach, incorporating monocyte counts alongside neutrophils and lymphocytes. These indices aim to capture the multifaceted nature of inflammation more accurately than single-cell ratios can, potentially offering enhanced sensitivity and specificity.
Yang et al.’s meta-analysis evaluates the alterations in these markers in adults with established obesity, analyzing data extracted from a wide array of clinical studies. Their findings reveal that individuals with obesity tend to exhibit elevated levels of NLR, PLR, SII, and SIRI compared to lean controls, suggesting that these indices could indeed reflect the inflammatory status characteristic of adiposity. However, the magnitude and consistency of these associations vary significantly across studies, highlighting underlying heterogeneity.
Several factors contribute to this variability. Differences in study design, population demographics, comorbidities, and methodological approaches—such as the timing and conditions of blood sample collection—may affect biomarker levels. Moreover, obesity itself is heterogeneous, with variations in fat distribution, metabolic health, and inflammation degree influencing immune-inflammatory profiles. These complexities underscore the need for standardized protocols and consideration of confounding factors when applying these indices clinically or in research.
Importantly, the meta-analysis identifies that age, sex, and geographic location serve as potential moderators influencing the association between immune-inflammatory markers and obesity. For instance, older individuals may exhibit higher baseline inflammation due to immunosenescence, potentially inflating NLR and related indices independent of obesity status. Similarly, sex differences in immune function—driven by hormonal influences—modulate inflammatory responses, necessitating tailored interpretation of biomarker data.
Clinical implications of these findings are both promising and cautionary. On one hand, using routine blood parameters to monitor systemic inflammation in obesity could facilitate early detection of metabolic complications, guide individualized therapeutic interventions, and track responses to weight loss or anti-inflammatory treatments. Such biomarkers could be integrated into risk stratification models, improving patient management and outcomes. On the other hand, without standardized thresholds and comprehensive understanding of confounding variables, reliance on these indices could lead to misinterpretation or overestimation of inflammatory burden.
The study also highlights potential avenues for future research. Longitudinal studies are needed to elucidate how changes in NLR, PLR, SII, and SIRI correspond with weight fluctuations, metabolic improvements, or the development of obesity-related complications. Exploration of these indices in diverse ethnic populations and across different obesity phenotypes could unravel patterns masked in aggregated analyses. Additionally, combining these systemic markers with tissue-specific inflammatory assessments or advanced molecular profiling might enhance the precision of obesity inflammation phenotyping.
Technological advancements in hematological analysis and biomarker discovery may also expand the repertoire of accessible inflammation indices. Integration of artificial intelligence and machine learning could refine the predictive power of combined hematological parameters beyond conventional ratios, potentially uncovering novel patterns linked to inflammatory trajectories in obesity. Such interdisciplinary approaches promise to revolutionize how we monitor and intervene in obesity-related inflammation.
In conclusion, the meta-analytic work of Yang and colleagues marks a pivotal step in validating peripheral blood-based immune-inflammatory markers as reflections of obesity-associated inflammation. While these indices offer valuable windows into the systemic inflammatory state, their clinical application demands nuanced understanding of biological and methodological heterogeneity. As obesity continues to impose a global health burden, harnessing such accessible biomarkers effectively could transform inflammation monitoring and pave the way for personalized therapeutic strategies in metabolic health.
The ongoing challenge lies in bridging the gap between research findings and pragmatic clinical tools. Translating these insights into standardized diagnostic or prognostic criteria necessitates collaborative efforts linking laboratory science, clinical medicine, and population health. As the field advances, the integration of immune-inflammatory indices with broader metabolic and cardiovascular risk assessments holds the potential to enhance precision medicine approaches for individuals grappling with obesity and its myriad complications.
Ultimately, the promise of routine hematological indices as beacons of obesity-associated inflammation underscores the evolving understanding of obesity as an immune-mediated condition. This paradigm shift opens new frontiers in both the basic science and clinical management of metabolic diseases, fostering hope for innovative interventions that target the inflammatory underpinnings of obesity to improve health outcomes worldwide.
Subject of Research: Association between immune-inflammatory biomarkers and obesity in adults
Article Title: Association between immune-inflammatory biomarkers (NLR, PLR, SII, SIRI) and obesity in adults: a systematic review and meta-analysis
Article References:
Yang, Y., Wang, J., Cai, J. et al. Association between immune-inflammatory biomarkers (NLR, PLR, SII, SIRI) and obesity in adults: a systematic review and meta-analysis. Int J Obes (2026). https://doi.org/10.1038/s41366-026-02108-0
Image Credits: AI Generated
DOI: 13 June 2026
Tags: chronic inflammation and obesityhematological markers of inflammationimmune biomarkers in adult obesityimmune-inflammatory markers blood testsinflammation and metabolic disorderslow-grade systemic inflammation obesitymeta-analysis of obesity biomarkersneutrophil-to-lymphocyte ratio in obesityobesity-associated immune responseplatelet-to-lymphocyte ratio significancesystemic immune-inflammation index rolesystemic inflammation response index analysis
